- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
January 31, 2023Christopher Larus Named Finalist for Legaltech News’ Leaders in Tech Law Award for Innovator of The Year
-
January 30, 2023David Martinez Named To 2023 Leaders of Influence: Minority Attorneys by Los Angeles Business Journal
-
January 25, 2023Roman Silberfeld Named to Daily Journal’s Inaugural Leading Commercial Litigators List
-
February 17-18, 2023MAJ 2023 Mid-Winter Meeting
-
February 24, 20232023 Appellate Practice Institute
-
March 3, 2023LGBTQ Legal Services: Transgender Name Change Clinic
-
Fourth QuarterGenerically Speaking: A Hatch-Waxman Litigation Bulletin
-
Fourth QuarterANDA Approvals
-
January 24, 2023Briefly: Column to Continue With New Authors at Helm
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Prescription Drugs and Design Defect Liability
By Eric Lindenfeld
2016
District judges apply three approaches to Section 402A of the Second Restatement of Torts in dealing with prescription drugs and design defect liability: the case-by-case approach, the blanket immunity approach, and the Third Restatement’s approach. Given the fundamental disagreements between these three approaches, this Article argues that the blanket immunity approach— employed by the minority of the courts—offers the most consistency, is the most equitable, and is socially and economically beneficial. In doing so, this Article examines the role of the FDA regulatory process in approving prescription drug designs, as well as the proper role of courts in reviewing claims of defectively designed pharmaceutical products. Additionally, this Article argues that the U.S. Supreme Court’s growing skepticism of the current state of state tort liability and the recent trend of preempting all state court tort claims, indicates the need for state courts employing the case-by-case approach to adopt the blanket immunity approach instead. Under the blanket immunity approach, the tort system does not unduly interfere with the FDA’s regulatory scheme, and still serves its compensatory role in pharmaceutical liability by allowing for negligence claims. Decisions regarding whether a drug’s benefits outweigh its risks are essentially left to those who are better equipped to make those decisions. The blanket immunity approach’s preclusion of strict liability also keeps costs associated with litigation at a minimum—leading to lower costs of medication and a greater incentive to innovate.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Eric M. Lindenfeld
Associate
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.